For research use only. Not for therapeutic Use.
Flunisolide (Cat.No:I000040) is a corticosteroid often used to treat allergic rhinitis.The principal mechanism of action of Flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.
| Catalog Number | I000040 |
| CAS Number | 3385-03-3 |
| Synonyms | (6α,11β,16α)-6-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 6α-Fluoro-11β,21-dihydroxy-16α,17α-(isopropylidenedioxy)?pregna-1,4-diene-3,20-dione; Aerobid; Aerobid M; Bronalide; Flunisolide; Lunis; Nasalide; |
| Molecular Formula | C24H31FO6 |
| Purity | ≥95% |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| InChI | InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 |
| InChIKey | XSFJVAJPIHIPKU-XWCQMRHXSA-N |
| SMILES | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O |
| Reference | </br>1:Quality by design (QbD) approach for design and development of drug-device combination products: A case study on flunisolide nasal spray. Chudiwal SS, Dehghan MH.Pharm Dev Technol. 2016 Sep 10:1-29. [Epub ahead of print] PMID: 27616074 </br>2:Flunisolide hydrofluoroalkane with integrated spacer for treating asthma: an updated review. Berger WE, Tashkin DP.Allergy Asthma Proc. 2015 Mar-Apr;36(2):105-15. doi: 10.2500/aap.2015.36.3835. Epub 2015 Jan 29. Review. PMID: 25635610 </br>3:Flunisolide for the treatment of asthma. Melani AS.Expert Rev Clin Pharmacol. 2014 May;7(3):251-8. doi: 10.1586/17512433.2014.908117. Epub 2014 Apr 9. Review. PMID: 24716719 </br>4:Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. Bensch GW, Greos LS, Gawchik S, Kpamegan E, Newman KB.Ann Allergy Asthma Immunol. 2011 Oct;107(4):323-9. doi: 10.1016/j.anai.2011.07.017. Epub 2011 Sep 3. PMID: 21962092 </br>5:Hyalinization of the pyloric stomach in CD-1 mice following oral (dietary) administration of the corticosteroid agonists mometasone furoate, budesonide, and flunisolide. McKevitt TP, Giffen P, Woodfine JA, McCawley SJ, Papworth SA, McGill P, Osborne J, Beard P, Williams TC, Klapwijk J, Lewis DJ.Toxicol Pathol. 2011 Oct;39(6):958-68. doi: 10.1177/0192623311418681. Epub 2011 Sep 1. PMID: 21885873 </br>6:Intranasal flunisolide treatment in patients with non-allergic rhinitis. Varricchio A, Capasso M, De Lucia A, Avvisati F, Varricchio AM, Bettoncelli G, Ciprandi G.Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):401-9. PMID: 21658314 </br>7:Modulation by flunisolide of tumor necrosis factor-alpha-induced stimulation of airway epithelial cell activities related to eosinophil inflammation. Boero S, Silvestri M, Ullmann N, Rossi GA.J Asthma. 2010 May;47(4):381-7. doi: 10.3109/02770901003759410. PMID: 20528590 </br>8:Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule. Food and Drug Administration, HHS..Fed Regist. 2010 Apr 14;75(71):19213-41. PMID: 20391646 Free Article</br>9:Prevention of surgery in children with adenoidal hypertrophy treated with intranasal flunisolide: a 12-month follow-up. Varricchio A, Tortoriello G, Capasso M, De Lucia A, Marchisio P, Varricchio AM, Mansi N, Giordano L, Liberatore G, Di Gioacchino M, Ciprandi G.J Biol Regul Homeost Agents. 2009 Apr-Jun;23(2):95-101. PMID: 19589290 </br>10:High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. Decimo F, Maiello N, Miraglia Del Giudice M, Amelio R, Capristo C, Capristo AF.Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):363-70. PMID: 19505390 |
